OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) Stock Short Interest Report for October

OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) saw a large increase in short interest in the month of October. As of October 15th, there was short interest totaling 76,652 shares, an increase of 121.3% from the September 30th total of 34,643 shares. Based on an average daily volume of 42,929 shares, the days-to-cover ratio is presently 1.8 days. Currently, 0.2% of the shares of the company are sold short.

OKYO Pharma Price Performance

Shares of OKYO stock traded down $0.05 during trading hours on Friday, reaching $1.45. 97,439 shares of the company’s stock were exchanged, compared to its average volume of 136,501. OKYO Pharma has a 1 year low of $1.26 and a 1 year high of $3.20. The stock’s fifty day moving average price is $1.44 and its two-hundred day moving average price is $1.64.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on OKYO. HC Wainwright reissued a “buy” rating on shares of OKYO Pharma in a research note on Wednesday, October 7th. Weiss Ratings restated a “sell (d-)” rating on shares of OKYO Pharma in a research note on Thursday, October 15th. Three analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, OKYO Pharma has an average rating of “Moderate Buy” and a consensus price target of $5.67.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in OKYO Pharma stock. Opaleye Management Inc. purchased a new position in shares of OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 375,204 shares of the company’s stock, valued at approximately $563,000. Opaleye Management Inc. owned about 0.71% of OKYO Pharma at the end of the most recent quarter. Institutional investors own 2.97% of the company’s stock.

OKYO Pharma Company Profile

OKYO Pharma Limited (NASDAQ:OKYO) is a clinical-stage biopharmaceutical company focused on developing precision medicines for inflammatory, ocular and pain-related diseases. The company’s research is centered on G protein-coupled receptors (GPCRs), a broad class of biological targets involved in regulating immune responses, pain signaling and other disease processes.

OKYO’s lead development program, OK-101, is a novel GPCR-targeting therapeutic being investigated for conditions including dry eye disease and neuropathic pain.